Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theratechnologies Inc (THTX)
NASDAQ:THTX
Theratechnologies (THTX) Stock Price & Analysis
167 Followers
THTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.88 - $4.20
Previous Close$1.31
Volume23.12K
Average Volume (3M)32.75K
Market Cap
$60.41M
Enterprise Value$95.77M
Total Cash (Recent Filing)$22.87M
Total Debt (Recent Filing)$58.24M
Price to Earnings (P/E)-2.1
Beta0.59
Next Earnings
Jul 11, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding45,980,019
10 Day Avg. Volume20,876
30 Day Avg. Volume32,749
Standard Deviation0.28
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.11
Price to Sales (P/S)2.81
Price to Cash Flow (P/CF)2.80
P/FCF Ratio1.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda-5.71
Forecast
1Y Price Target
$4.00Price Target Upside203.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Theratechnologies News
PremiumCompany Announcements
Theratechnologies Shareholders Elect Directors, Appoint Auditors
PremiumCompany Announcements
Theratechnologies Announces New Board Chair
PremiumCompany Announcements
Theratechnologies Elects New Board Chair
PremiumCompany Announcements
Theratechnologies Announces Virtual Annual Meeting
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company has achieved its highest quarterly revenue on record, indicating robust financial health and promising growth.
Financial StrategyA capital raise is expected to ease liquidity concerns, providing the company with a more solid financial base for future operations.
Market ValuationThe market currently undervalues the potential of the company's commercial portfolio, suggesting room for growth as real value is recognized.
Bears Say
Financial ForecastThe terminal growth rate used in the analyst's risk-adjusted discounted cash flow analysis has been reduced from 4% to 2%.
Product Efficacy ConcernTrogarzo IM injection did not meet equivalence limits to IV injection.
Regulatory SetbackThe company received a refusal to file letter from the FDA regarding its sBLA application for Trogarzo.
---
Ownership Overview
40.95% Insiders
0.06% Mutual Funds
24.87% Other Institutional Investors
34.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
THTX FAQ
What was Theratechnologies Inc’s price range in the past 12 months?
Theratechnologies Inc lowest stock price was $0.88 and its highest was $4.20 in the past 12 months.
What is Theratechnologies Inc’s market cap?
Currently, no data Available
When is Theratechnologies Inc’s upcoming earnings report date?
Theratechnologies Inc’s upcoming earnings report date is Jul 11, 2024 which is in 54 days.
How were Theratechnologies Inc’s earnings last quarter?
Theratechnologies Inc released its earnings results on Apr 10, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.118 by $0.018.
Is Theratechnologies Inc overvalued?
According to Wall Street analysts Theratechnologies Inc’s price is currently Undervalued.
Does Theratechnologies Inc pay dividends?
Theratechnologies Inc does not currently pay dividends.
What is Theratechnologies Inc’s EPS estimate?
Theratechnologies Inc’s EPS estimate is -$0.04.
How many shares outstanding does Theratechnologies Inc have?
Theratechnologies Inc has 45,980,020 shares outstanding.
What happened to Theratechnologies Inc’s price movement after its last earnings report?
Theratechnologies Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.118. Following the earnings report the stock price went down -3.896%.
Which hedge fund is a major shareholder of Theratechnologies Inc?
Currently, no hedge funds are holding shares in THTX
---
Theratechnologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (203.03% Upside)
$4.00 (203.03% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.02%
Trailing 12-Months
Company Description
Theratechnologies Inc
Theratechnologies, Inc. is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies was founded on October 19, 1993 and is headquartered in Montreal, Canada.
---
THTX Earnings Call
Q1 2024
0:00 / 0:00
---
THTX Stock 12 Month Forecast
Average Price Target
$4.00
▲(203.03% Upside)
Technical Analysis
Best Analysts Covering THTX
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-8.10%
reiterated a buy rating 10 months ago
Copying Douglas Loe's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -8.10% per trade.
---